Methods for treating bacterial infection
View Patent ↗The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.
1. A method of suppressing bacterial infection comprising:
administering ML 141 or its analogs to cells infected by Staphylococcus,
where the analogs are defined by the following structure:
where
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is hydrogen, and R and Ar are phenylmethylene (-Ph-(2-CH 2 )—), wherein the phenyl is attached to the Ar position and the methylene is attached to the R position;
or
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is methyl, R is hydrogen, and Ar is phenyl;
or
Ar′ is halophenyl (-Ph-halogen), R′ is hydrogen, R is hydrogen, and Ar is phenylpolyethylene glycol methyl ether (-Ph-(O—CH 2 —CH 2 ) n —O-Me) wherein n is any integer.
2. The method of claim 1 wherein said bacterial infection is from Staphylococcus aureus.
3. The method of claim 1 wherein administering includes providing ML 141 or its analogs adjacent to the cells.
4. The method of claim 1 wherein administering includes testing ML 141 on the cells.
5. The method of claim 1 wherein administering includes testing at least one analog on the cells.
6. The method of claim 1 wherein suppressing bacterial infection includes suppressing initial bacterial infection.
7. The method of claim 1 wherein suppressing bacterial infection includes suppressing persistent bacterial infection.
8. The method of claim 7 wherein administering includes providing approximately 1 μM of ML 141 or its analogs.
9. The method of claim 7 wherein administering includes providing approximately 10 μM of ML 141 or its analogs.
10. The method of claim 1 wherein administering occurs subsequent to the onset of bacterial infection.
11. The method of claim 1 wherein the cells are animal cells.
12. The method of claim 1 wherein the cells are human cells.
13. The method of claim 1 wherein the cells express CDC42.
14. A method of suppressing bacterial infection, comprising:
providing a chemical defined by the following structure:
where
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is hydrogen, and R and Ar are phenylmethylene (-Ph-(2-CH 2 )—), wherein the phenyl is attached to the Ar position and the methylene is attached to the R position;
or
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is methyl, R is hydrogen, and Ar is phenyl;
or
Ar′ is halophenyl (-Ph-halogen), R′ is hydrogen, R is hydrogen, and Ar is phenylpolyethylene glycol methyl ether (-Ph-(O—CH 2 —CH 2 ) n —O-Me) wherein n is any integer; and
providing the chemical to cells infected by Staphylococcus.
15. The method of claim 14 further comprising providing a pharmaceutically accepted solvent or delivery vehicle selected from the group consisting of polyethylene glycol (PEG), dimethyl sulfoxide, ethanol, and combinations thereof.
16. The method of claim 15 wherein the solvent or delivery vehicle is polyethylene glycol.
17. The method of claim 14 wherein the halophenyl is chlorophenyl.
18. A method of suppressing bacterial infection comprising:
administering ML 141 or its analogs to a patient infected by bacteria of the genus Staphylococcus,
where the analogs are defined by the following structure:
where
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is hydrogen, and R and Ar are phenylmethylene (-Ph-(2-CH 2 )—), wherein the phenyl is attached to the Ar position and the methylene is attached to the R position;
or
Ar′ is methoxyphenyl (-Ph-O-Me), R′ is methyl, R is hydrogen, and Ar is phenyl;
or
Ar′ is halophenyl (-Ph-halogen), R′ is hydrogen, R is hydrogen, and Ar is phenylpolyethylene glycol methyl ether (-Ph-(O—CH 2 —CH 2 ) n —O-Me) wherein n is any integer.